Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Disease 1

Interventions

Cyclophosphamide 1499Cisplatin 1436Paclitaxel 1342Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1135Bevacizumab 1071Fluorouracil 907Doxorubicin 805Dexamethasone 755Rituximab 745Capecitabine 736Oxaliplatin 710pembrolizumab 700Etoposide 679Irinotecan 641Filgrastim 624Nivolumab 588Cytarabine 587Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 437

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × lortalamine × Clear all
NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed
531 enrolled
Genitourinary

Disease, Prostatic Neoplasms

NCT00925275 2010-05-04

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Cellectar, Inc

Phase 1 Completed
9 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡